Viatris (VTRS)

Health Care · $23.3B market cap · SEC CIK 0001792044

Next reports on Feb 24, 2027, after the close, with analysts expecting $0.63 in earnings per share.

52-week range $9.92 to $20.53. At its 52-week high and 110% above its low.

The case for VTRS

• Free cash flow of 8.3% of its market value a year: a lot of cash for the price.
• Pays a 5.1% dividend while you wait.
• Trades at 1.30× book value, close to what the balance sheet says it owns.
• Within 1% of its 52-week high: the trend is up.
• Up 102.5% over the past year.

The case against

• Losing money over the last year: net margin −2.8%, return on equity −3%.
• Long-term debt of $12.5B would take 5 years of operating cash flow to repay.
• Pays a dividend while losing money over the last twelve months.
• Growth is weak (35/100): revenue +4.4%, +3.7% a year over five years.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• It is losing money, so it has no P/E; that counts against value rather than being skipped.
• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Viatris's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Viatris says it does

About Viatris Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges. Viatris’ executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more…

Risk factors VTRS lists in its 10-K

• A significant portion of our revenues is derived from sales to a limited number of customers.”
• Healthcare reform legislation could have a material adverse effect on our business
• We have significant operations globally, which exposes us to the risks inherent in conducting our business internationally
• Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price
• The illegal distribution and sale by third parties of counterfeit or IP-infringing versions of our products or of diverted or stolen products could have a negative impact on our reputation and our business
• We face vigorous competition that threatens the commercial acceptance and pricing of our products
• A relatively small group of products may represent a significant portion of our revenues, net sales, gross profit, or net earnings from time to time
• Current and changing economic conditions, including inflation, may adversely affect our industry, business, partners and suppliers
• The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations
• If we are unable to successfully introduce new products in a timely manner, our future revenue and profitability may be adversely affected
• We expend a significant amount of resources on R&D efforts that may not lead to successful product introductions
• Even if our products in development receive regulatory approval, such products may not achieve expected levels of market acceptance
• We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process
• Our future success is highly dependent on our ability to attract, motivate and retain key personnel
• We rely on the effectiveness of our patents, trademarks, confidentiality agreements and other measures to protect our intellectual property rights
• We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries
• We are increasingly dependent on IT and information systems and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks
• Our business and operations are subject to risks related to climate change
• There can be no guarantee that we will continue to pay dividends or repurchase shares under our share repurchase program
• If tax authorities determine that the intercompany pricing applied to our cross-border arrangements is inconsistent with the arms’ length standard or otherwise ineffective, our tax liabilities could increase
• We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders
• Unanticipated changes in our tax provisions or exposure to additional income tax liabilities and changes in income tax laws and tax rulings may have a significant adverse impact on our effective tax rate and income tax expense
• Viatris may be subject to significant U.S. tax liabilities or be obligated to indemnify Pfizer for any such tax liability imposed on Pfizer in connection with the Combination
• We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis
• Viatris has suffered and in the future could suffer additional losses due to impairment charges
• Goodwill and Other Intangible Assets
• Viatris may be adversely affected by disruptions in the credit markets, including disruptions that reduce customers’ access to credit and increase the costs to customers of obtaining credit
• Viatris has certain material obligations relating to defined benefit pension and termination benefit programs
• The market price of our common stock has been and may continue to be volatile, and the value of your investment could materially decline
• The expansion of social media platforms presents new risks and challenges
• Provisions in the Viatris Charter and Viatris Bylaws and of applicable law may prevent or delay an acquisition of Viatris, which could decrease the trading price of Viatris common stock
• The exclusive forum provisions in the Viatris Charter could discourage lawsuits against Viatris and its directors and officers

Filings

Other Health Care companies